Sigilon Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview

Sigilon Therapeutics

08/05/2023 12:26

* Sigilon Therapeutics Inc  SGTX.OQ   SGTX.O  is expected
to show
a fall in quarterly revenue when it reports  results on May 10
(estimated). 
    * The Cambridge Massachusetts-based  company is expected to
report
 a 2.1% decrease in revenue to $3.1 million from $3.17 million a
year ago, according to the estimate from one analyst, based on
Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Sigilon
Therapeutics Inc
is for a loss of 23 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Sigilon
Therapeutics Inc is $4​, above​ its last closing price of $0.50.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.33       -0.38      -0.21     Beat    44.4
 Sep. 30 2022  -0.43       -0.42      -0.27     Beat    36.5
 Jun. 30 2022  -0.44       -0.43      -0.44     Missed  -1.7​
 Mar. 31 2022  -0.33       -0.33      -0.43     Missed  -29.3
 ​​Dec.        -0.56       -0.56      -0.55     Beat    2.1
 31 2021                                                
 Sep. 30 2021  -0.70       -0.66      -0.63     Beat    4.3​
 Jun. 30 2021  -0.57       -0.63      -0.65     Missed  -3.6
 Mar. 31 2021  -0.61       -0.59      -0.60     Missed  -1.1
 This summary was machine generated May 8 at 11:26 GMT.  All
figures in US dollars  unless otherwise stated